Geron Corporation (NASDAQ: GERN) is a biopharmaceutical company focused on developing biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including heart failure, spinal cord injury and diabetes. The company’s mission is to develop an array of anti-cancer therapies based on telomerase inhibitors, telomerase therapeutic vaccines, and telomerase-based oncolytic viruses, and diagnostics based on telomerase detection. For further information, visit the Company’s web site at www.geron.com.
- 18 years ago
QualityStocks
Geron Corporation (NASDAQ: GERN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Belden Inc. (NYSE: BDC) To Acquire RUCKUS Networks for $1.85 Billion
Belden (NYSE: BDC) announced it has entered into a definitive agreement to acquire RUCKUS Networks from Vistance Networks for approximately $1.85…
-
From Capital to Catalysts: Canamera Energy Metals Corp.’s (CSE: EMET) (OTCQB: EMETF) $10M Raise Sets the Stage for Rare Earth Exploration Momentum
Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF)and may include paid…
-
Forward Industries Inc. (NASDAQ: FWDI) Adds Digital Asset and Traditional Finance Executive Mark Brazier as Chief Financial Officer
Forward Industries has appointed experienced financial executive Mark Brazier to serve as Chief Financial Officer.…